Galectin-3 in Biliary Atresia and Other Pediatric Cholestatic Liver Diseases.
Dor YoeliCara L MackYuhuan LuoAlexander ChaidezNathaly Limon De La RosaZhaohui WangEduardo Cervantes-AlvarezChristene A HuangNalu Navarro-AlvarezPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2023)
Plasma Galectin-3 is higher in late BA at time of transplant in comparison to early BA at time of Kasai. The number of Galectin-3 expressing M2 macrophages in late BA is elevated relative to late other CLD and was associated with other prognostic histological findings. Galectin-3 targeted therapy may be beneficial in slowing disease progression to cirrhosis in children with BA.
Keyphrases